HRP950507B1 - 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO(1,2-a)PYRAZINE DERIVATIVES - Google Patents

2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO(1,2-a)PYRAZINE DERIVATIVES

Info

Publication number
HRP950507B1
HRP950507B1 HR950507A HRP950507A HRP950507B1 HR P950507 B1 HRP950507 B1 HR P950507B1 HR 950507 A HR950507 A HR 950507A HR P950507 A HRP950507 A HR P950507A HR P950507 B1 HRP950507 B1 HR P950507B1
Authority
HR
Croatia
Prior art keywords
pct
pyrido
pyrazine derivatives
sec
substituted octahydro
Prior art date
Application number
HR950507A
Other languages
English (en)
Inventor
Kishor A Desai
Anton F J Fliri
Mark A Sanner
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HRP950507A2 publication Critical patent/HRP950507A2/hr
Publication of HRP950507B1 publication Critical patent/HRP950507B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR950507A 1994-09-30 1995-09-29 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO(1,2-a)PYRAZINE DERIVATIVES HRP950507B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31547094A 1994-09-30 1994-09-30

Publications (2)

Publication Number Publication Date
HRP950507A2 HRP950507A2 (en) 1997-08-31
HRP950507B1 true HRP950507B1 (en) 2002-06-30

Family

ID=23224581

Family Applications (1)

Application Number Title Priority Date Filing Date
HR950507A HRP950507B1 (en) 1994-09-30 1995-09-29 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO(1,2-a)PYRAZINE DERIVATIVES

Country Status (34)

Country Link
US (1) US5852031A (fr)
EP (1) EP0783503B1 (fr)
JP (1) JP3287574B2 (fr)
KR (1) KR100244848B1 (fr)
CN (1) CN1068327C (fr)
AT (1) ATE209648T1 (fr)
AU (1) AU681310B2 (fr)
BR (1) BR9504230A (fr)
CA (1) CA2200959C (fr)
CO (1) CO4410335A1 (fr)
CZ (1) CZ285090B6 (fr)
DE (1) DE69524241T2 (fr)
DK (1) DK0783503T3 (fr)
ES (1) ES2166830T3 (fr)
FI (1) FI113655B (fr)
HR (1) HRP950507B1 (fr)
HU (1) HUT77354A (fr)
IL (1) IL115384A (fr)
MX (1) MX9702350A (fr)
MY (1) MY113729A (fr)
NO (1) NO308995B1 (fr)
NZ (1) NZ290936A (fr)
PE (1) PE47196A1 (fr)
PL (1) PL180899B1 (fr)
PT (1) PT783503E (fr)
RU (1) RU2163239C2 (fr)
SI (1) SI9520096A (fr)
SK (1) SK284341B6 (fr)
TR (1) TR199501194A2 (fr)
TW (1) TW406081B (fr)
UA (1) UA50720C2 (fr)
WO (1) WO1996010571A1 (fr)
YU (1) YU63795A (fr)
ZA (1) ZA958223B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) * 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
JP3204456B2 (ja) * 1995-12-21 2001-09-04 ファイザー・インコーポレーテッド ２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体
US6281216B1 (en) * 1998-02-09 2001-08-28 Duphar International Research B.V. 2-aminoquinoline derivatives having d4-agonistic activity
EP0953567A3 (fr) * 1998-04-29 2003-04-02 Pfizer Products Inc. Dérivés de piperazin-, piperidine- et tetrahydropyridine bicyclique substitués, leur préparation et leur utilisation comme agents a activité dopaminergique (recepteur D4 de la dopamine) centrale
GT199900060A (es) * 1998-05-22 2000-10-14 Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmacèuticas.
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0011013D0 (en) * 2000-05-09 2000-06-28 Astrazeneca Ab Chemical compounds
EP1177792A3 (fr) * 2000-07-27 2002-10-23 Pfizer Products Inc. Ligands dopamine d4 destines au traitement des troubles associees a la cherche de la nouveaute
US6670476B2 (en) 2000-11-29 2003-12-30 Pfizer Inc. Resolution of trans-7-(hydroxy-methyl)octa-hydro-2H-pyrido[1,2-a]pyrazine
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3388128A (en) * 1965-09-03 1968-06-11 Allan R. Day Substituted 1, 4-diazabicyclo [4. 4. 9] decanes
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4517187A (en) * 1982-10-18 1985-05-14 Pennwalt Corporation 1,3,4,6,7-11b-Hexahydro-7-phenyl-2H-pyrazino[2,1-a]isoquinolines methods of preparation, and use as antidepressants
DE3564683D1 (en) * 1984-08-07 1988-10-06 Cortial 4-(arylpiperazinylethylaminoethoxy) phenol derivatives, process for their preparation and their therapeutical application
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
IT1204803B (it) * 1986-02-17 1989-03-10 Acraf Composto farmacologicamente attivo e composizioni farmaceutiche che lo contengono,procedimento per prepararlo e intermedio utile in detto procedimento
US4788290A (en) * 1987-12-11 1988-11-29 American Home Products Corporation Serotonergic pyrazine derivatives
SE8803429D0 (sv) * 1988-09-28 1988-09-28 Pharmacia Ab Novel pyridyl- and pyrimidyl derivatives
WO1990008148A1 (fr) * 1989-01-23 1990-07-26 Pfizer Inc. Agents anxiolytiques bis-aza-bicycliques
ES2072141T3 (es) * 1991-01-31 1995-07-01 Pfizer Resolucion de trans-2-(2-pirimidinil)-7-(hidroximetil)octahidro-2h-pirido(1,2a)pirazina.
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
US5185449A (en) * 1991-02-27 1993-02-09 Pfizer Inc. Process and intermediate for certain bis-aza-bicyclic anxiolytic agents
CA2195622C (fr) * 1991-02-27 1999-08-17 Frank J. Urban Methode de preparation de trans-piperidine-2,5-dicarboxylates
EP0607163B1 (fr) * 1991-09-25 1996-12-11 Pfizer Inc. 2-SUBSTITUEES PERHYDRO-1-H-PYRIDO[1,2-a]PYRAZINES UTILISES COMME NEUROLEPTIQUES
JP2753146B2 (ja) * 1992-06-16 1998-05-18 ファイザー・インコーポレーテッド ビス−アザー二環式抗不安薬の製法および中間体
ES2133416T3 (es) * 1992-10-23 1999-09-16 Merck Sharp & Dohme Ligandos de subtipos de receptores de dopamina.
JPH08502958A (ja) * 1992-10-23 1996-04-02 メルク シヤープ エンド ドーム リミテツド ドーパミンレセプターサブタイプリガンド
EP0687267B1 (fr) * 1993-03-01 1999-09-01 MERCK SHARP & DOHME LTD. Derives de pyrrolo-pyridine comme ligands des recepteurs dopamine
US5576319A (en) * 1993-03-01 1996-11-19 Merck, Sharp & Dohme Ltd. Pyrrolo-pyridine derivatives
PL310443A1 (en) * 1993-03-01 1995-12-11 Merck Sharp & Dohme Derivatives of pyrolo-pyridine
JPH08508466A (ja) * 1993-03-05 1996-09-10 メルク シヤープ エンド ドーム リミテツド ドーパミンｄ４リガンドとしてのキノロン誘導体
GB9416162D0 (en) * 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
DK0783503T3 (da) 2002-02-11
RU2163239C2 (ru) 2001-02-20
MX9702350A (es) 1997-06-28
PL319636A1 (en) 1997-08-18
EP0783503B1 (fr) 2001-11-28
NO308995B1 (no) 2000-11-27
DE69524241T2 (de) 2002-06-13
PL180899B1 (pl) 2001-04-30
AU681310B2 (en) 1997-08-21
JP3287574B2 (ja) 2002-06-04
TR199501194A2 (tr) 1996-06-21
HUT77354A (hu) 1998-03-30
NO971416L (no) 1997-05-20
JPH09511527A (ja) 1997-11-18
FI971310A0 (fi) 1997-03-27
SI9520096A (sl) 1998-04-30
US5852031A (en) 1998-12-22
CN1168672A (zh) 1997-12-24
ZA958223B (en) 1997-04-01
YU63795A (sh) 1999-03-04
SK284341B6 (sk) 2005-02-04
IL115384A0 (en) 1995-12-31
KR100244848B1 (ko) 2000-03-02
CN1068327C (zh) 2001-07-11
UA50720C2 (uk) 2002-11-15
IL115384A (en) 1999-10-28
NZ290936A (en) 1998-01-26
ATE209648T1 (de) 2001-12-15
BR9504230A (pt) 1996-08-06
NO971416D0 (no) 1997-03-25
CA2200959A1 (fr) 1996-04-11
PE47196A1 (es) 1996-11-11
FI113655B (fi) 2004-05-31
HRP950507A2 (en) 1997-08-31
CZ285090B6 (cs) 1999-05-12
DE69524241D1 (de) 2002-01-10
EP0783503A1 (fr) 1997-07-16
CZ94797A3 (cs) 1998-07-15
KR970706282A (ko) 1997-11-03
SK32597A3 (en) 1998-09-09
WO1996010571A1 (fr) 1996-04-11
TW406081B (en) 2000-09-21
CA2200959C (fr) 2000-05-23
ES2166830T3 (es) 2002-05-01
AU3189395A (en) 1996-04-26
MY113729A (en) 2002-05-31
FI971310A (fi) 1997-03-27
CO4410335A1 (es) 1997-01-09
PT783503E (pt) 2002-03-28

Similar Documents

Publication Publication Date Title
PL309348A1 (en) Application of an agent called riluzole in therapy of neurological damages caused by or associated with injuries
MY107157A (en) Quinuclidine derivatives.
IL108284A0 (en) Use of riluzole for the treatment of parkinson's disease and parkinsonian syndromes
AP1456A (en) Pharmaceutical agents for the treatment of parkinson's disease, ADHD and microadenomas.
ZA958223B (en) 2,7-Substituted octahydro-1h-pyrido[1,2-a]pyrazine derivatives
IL118167A0 (en) Pyrazolo (1,5a) pyrimidines their preparation and use
HUP0003118A2 (hu) 2,7-Szubsztituált oktahidro-1H-pirido-[1,2-a]pirazin-származékok alkalmazása gyógyszerkészítmények előállítására
DK671588D0 (da) Bisphenylalkylpiperazinderivater og fremgangsmaade til fremstilling deraf
AU3160995A (en) New 3-substituted 3h-2,3-benzodiazepine derivatives, their preparation and use as medicaments
IL103204A0 (en) Neuroleptic 2-substituted perhydro-1-h-pyrido(1,2-a)pyrazines
AU2560092A (en) Anti-allergic thiadiazolo(4,3-a)pyridine derivatives
PL311296A1 (en) Derivatives of benzo [f] quinoxalinodione, method of obtaining them and their application in therapeutic agents
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
HU913660D0 (en) The use of imidoazepine derivatives for treating of sleep impairments
IL108283A0 (en) Use of riluzole for promoting restoration following radiation

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20050314

Year of fee payment: 10

PBON Lapse due to non-payment of renewal fee

Effective date: 20050930